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Background. Prior study showed HCV-infected patients have increased serum N-Terminal Pro-B-Type Natriuretic Peptide (NT-
proBNP) and a possible left ventricular diastolic dysfunction. The objectives of the present paper were to investigate the
characteristics of hs-CRP and its correlation with clinical proﬁles including NT-proBNP and echocardiographic variables in HCV-
infected patients.Methodsand Results.A total of 106 HCV-infected patients and 106 controlhealthy individuals were enrolled. The
levelofserumhs-CRP(median1.023mg/L,range0.03∼5.379mg/L)wassigniﬁcantlylowerinall106patientsthanthatincontrols
(median 3.147mg/L, range 0.08∼7.36mg/L, P = 0.012). Although hs-CRP did not correlate signiﬁcantly with NT-proBNP when
all patients and controls were included (r = 0.169, P = 0.121), simple regression analysis demonstrated a statistically signiﬁcant
linear correlation between hs-CRP and NT-proBNP in HCV-infected patients group (r = 0.392, P = 0.017). Independent
correlates of hs-CRP levels (R2 = 0.13) were older age (β  = 0.031, P = 0.025) and NT proBNP (β  = 0.024, P = 0.017).
Conclusions. Although the level of serum hs-CRP decreased signiﬁcantly, there was a signiﬁcant association between hs-CRP and
NT-proBNP in HCV-infected patients.
1.Introduction
In the past decade, association of hepatitis C virus (HCV)
infection and cardiovascular diseases (CVD) has gained
importance because the high occurrence of hepatitis C
is a common source of infection worldwide. There have
been a series of studies focusing on associations between
HCV infection and CVD to investigate whether HCV is
a risk factor for development of CVD. Some investigators
have reported positive associations between HCV infection
and CVD including dilated cardiomyopathy, hypertrophy
cardiomyopathy, myocarditis, and coronary artery disease,
respectively [1–3]. Our previous study has shown that
patients with Hepatitis C virus infection have increased
serum N-Terminal Pro-B-Type Natriuretic Peptide (NT-
proBNP) and a possible subclinical left ventricular diastolic
dysfunctional evidence for a pathogenic link between HCV
and CVD [4].
C-reactive protein (CRP) is a biomarker for inﬂamma-
tion and is associated with increased coronary artery disease
and cardiovascular events [5, 6]. Regardless of whether CRP
plays a causal role in atherothrombosis, this biomarker
has been proposed to be useful for improving CVD-
risk prediction. In the most recent comprehensive meta-
analysis, high-sensitivity C-reactive protein (hs-CRP) was
consistently found to be an independent predictor of CVD
[7].Increasedhs-CRPhasbeenassociatedwithincreasedrisk
for development of hypertension, transient ischemic attack,
stroke, peripheral arterial disease, and sudden coronary
death [7]. However, the features of hs-CRP in HCV-infected
patients and whether hs-CRP is an appropriate surrogate
cardiovascular risk marker in HCV-infected population have
not been fully addressed.
Theaimofthisstudywastoinvestigatethecharacteristics
of hs-CRP and its correlation with clinical proﬁles including2 Mediators of Inﬂammation
NT-proBNP and echocardiographic variables in patients
with HCV infection.
2.MaterialsandMethods
The present study has been approved by the Ethics Commit-
tee of Shanghai Tenth People’s Hospital, Tongji University,
and performed according to the World Medical Association
Declaration of Helsinki.
2.1. Study Population. Patient population: from January
2008 to February 2011, one hundred and six consecutive
Chinese patients admitted to two diﬀerent hospitals with
well-deﬁned HCV infection were enrolled according to
following criteria. Inclusion criteria: positive for serum anti-
HCV antibody and HCV RNA. Exclusion criteria: HCV-
infected patients treated with interferon α in the past six
months or less, liver cirrhosis, other types of hepatitis or liver
disease of diﬀerent etiology, other infectious diseases, overt
cardiovascular disease (based on documented history and
ECG examination), endocrine diseases, lung disease, renal
dysfunction (serum creatinine level >2.0mg/dL), presence
or history of neoplastic diseases, pregnant or postpartum
women, and present or past history of alcohol or drug abuse.
Control population: healthy individuals whose age and
gender matched with HCV-infected patients were selected
randomly from the general population and served as a
control population. This control group was extracted from
a larger sample of 11800 subjects in a population-based
survey of plasma cholesterol levels. All enrolled had no
documented history of chronic systemic diseases including
CVD, renal disorders, liver disorders, and presence or history
of neoplastic diseases and autoimmune diseases.
All subjects gave their informed consent for participation
in the study, which was approved by the Ethics Committee of
Shanghai Tenth People s Hospital, Tongji University.
2.2. Laboratory Investigations. Before current initial treat-
ment of HCV infection with interferon α, venous blood
samples were collected under standardized conditions after
an overnight fast and centrifuged at 3,000g, and then the
separated serum was stored at −80◦C until analysis. Concen-
trations of serum hs-CRP were measured using an enzyme-
linked immunosorbent assay (ELISA) kits (RapidBio, West
Hills, CA, USA). Concentrations of serum NT-proBNP
were measured on an Elecsys 2010 instrument (Elecsys
2010, Roche Diagnostics, Mannheim, Germany). Anti-HCV
antibodywasmeasuredbyEIAgenHCVAbKit(AdaltisItalia
S.p.A). HCV RNA was quantiﬁed by Cobas Amplicor HCV
Test,Version2.0(RocheMolecularSystems,Inc.,Pleasanton,
CA). Glomerular ﬁltration rate was estimated using the four
variable MDRD formula as follows: GFR = 186.3 × (serum
creatinine − 1.154) × (age − 0.203) × 1.212 (if black) ×
0.742 (if female).
2.3. Echocardiographic Measurements. All HCV-infected
patients and controls were consecutively submitted to
transthoracic echocardiographic evaluation before current
Table 1: Baseline characteristics of subjects.
Variables Patients
(N = 106)
Controls
(N = 106) P value
Height (cm) 168.4 ±5.3 168.9 ±6.1 0.391
Weight (kg) 73.5 ±8.47 2 .9 ±7.7 0.588
SBP (mmHg) 124.6 ±13.1 125.3 ±12.3 0.689
DBP (mmHg) 76.3 ±8.07 5 .6 ±9.1 0.553
TC (mmol/L)∗ 3.81 ±0.52 3.62 ±0.50 0.007
Triglycerides (mmol/L) 1.12 ±0.46 1.17 ±0.57 0.483
BMI 22.26 ±3.34 22.52 ±3.17 0.562
Smoker (n, %) 12, 11.3 14, 13.2 0.832
Abbreviations: SBP, Systolic blood pressure; DBP, Diastolic blood pressure;
TC, total cholesterol.
Data are expressed as mean ± SD.
∗A P value of less than 0.05 was considered statistically signiﬁcant.
initial treatment with interferon α. Doppler echocardio-
graphic evaluation was conducted using Philips Sonos 5500,
with a 2∼4MHz transducer and for each evaluated parame-
ter,andthreemeasurementsweretaken.Twoobserversmade
the all assessments, respectively. The following measurable
parameters were analyzed: left ventricular diastolic diame-
ter (LVDd), left ventricular posterior wall diastolic thick-
ness (LVPWd), interventricular septum diastolic thickness
(IVSd), left ventricular ejection fraction (LVEF), fractional
shortening (FS), peak early diastolic transmitral ﬂow (E),
peak late diastolic transmitral ﬂow (A), the E/A ratio, and
E-wave deceleration time (DT). The early and late diastolic
velocities at the septal and lateral mitral annulus were
obtained from the apical 4-chamber view using Doppler
tissue imaging, and the values were averaged, respectively (E
 
and A ), and the ratio of E/E
  was calculated.
2.4. Statistical Analysis. Continuous data are expressed as
means ± standard deviation for the Gaussian-distributed
data and median (range, 25% ∼75%) for the non-Gaussian-
distributed data. Categorical data are expressed as propor-
tions (%). Student’s t-test or Mann-Whitney U-tests was
used to determine diﬀerences between groups for Gaussian-
distributed data or non-Gaussian-distributed data, where
appropriate. A chi-square test was used to compare propor-
tions. Linear regression analysis was performed to evaluate
the relationship between hs-CRP and clinical proﬁles.
A P value of less than 0.05 was considered statistically
signiﬁcant. Statistical analysis was performed using the
statistical package SPSS12.0.1 (SPSS Inc, Chicago, IL).
3. Results
3.1. Characteristics of the Study Group. A total of 106
patients with HCV infection (38 females, 68 males) aged
24 to 74 (51.1 ± 10.6) years were enrolled and 106 gender-
m a t c h e dc o n t r o l sa g e d2 5t o7 3( 5 0 .9 ± 11.0) years were
also recruited. The baseline characteristics are presented
in Table 1. Height, weight, systolic blood pressure (SBP),
diastolic blood pressure (DBP), triglyceride (TG), BMI,Mediators of Inﬂammation 3
Table 2: Clinical characteristics of patients group.
Variables Patients
Duration of hepatitis C (yr; means ± SD) 5.2 ±3.7
HCV RNA (copies/mL; median (25% ∼ 75%)) 3.74 × 106 (2.13 × 105 ∼ 2.43 × 107)
Serum albumin (g/L; means ± SD) 37.41 ±7.14
AST (IU/L; median (25% ∼ 75%)) 51.6 (28.4 ∼ 84.6)
ALT (IU/L; median (25% ∼ 75%)) 42.4 (26.9 ∼ 81.4)
LDH (IU/L; means ± SD) 181.4 ±46.4
Serum creatinine (mg/dL; median (25% ∼ 75%)) 0.81 (0.69 ∼ 0.93)
eGFR (mL·min−1·(1.73m−2)−1; means ± SD) 95.6 ±10.4
Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; eGFR, estimated glomerular ﬁltration rate.
Table 3: Echocardiographic features of patients with diﬀerent
serum NT-proBNP Levels.
Variables High level Normal level P value
NT-proBNP >125pg/mL <125pg/mL —
No. 17 89 —
LVDd (mm) 47.62 ±4.38 45.90 ±4.68 0.163
LVPWd (mm) 9.24 ±1.26 9.10 ±2.05 0.787
IVSd (mm) 9.10 ±1.64 8.95 ±1.72 0.741
E( c m / s ) ∗ 70.06 ±17.40 79.49 ±16.04 0.031
A( c m / s ) ∗ 98.90 ±19.72 73.27 ±12.40 <0.01
E/A∗ 0.75 ±0.16 1.14 ±0.36 <0.01
DT (ms)∗ 238.4 ±52.7 197.4 ±24.9 <0.01
E  (cm/s)∗ 6.24 ±1.24 9.91 ±2.61 <0.01
A  (cm/s)∗ 9.71 ±2.84 11.90 ±2.94 0.006
E/E ∗ 12.77 ±3.15 8.31 ±1.94 <0.01
LVEF (%) 64.90 ±6.62 67.05 ±4.01 0.075
FS (%) 39.52 ±5.32 41.62 ±4.68 0.100
Abbreviations: LVDd, left ventricular diastolic diameter; LVPWd, left ven-
tricular posterior wall diastolic thickening; IVSd, interventricular septum
diastolic thickening; E, peak early diastolic transmitral ﬂow; A, peak late
diastolic transmitral ﬂow; E , peak early diastolic annular velocity; A ,p e a k
late diastolic annular velocity; E/E , the ratio of E to E ;D T ,d e c e l e r a t i o n
time; LVEF, left ventricular ejection fraction; FS, fractional shortening.
Data are expressed as mean ± SD.
∗A P value of less than 0.05 was considered statistically signiﬁcant.
and proportion of smokers between groups showed no
signiﬁcantdiﬀerences.Totalcholesterol(TC)levelwashigher
in HCV-infected group (3.81 ± 0.52mmol/L versus 3.62 ±
0.50mmol/L, P = 0.007). The clinical characteristics of
patient group are given in Table 2.
3.2. Comparison of Serum hs-CRP and NT-ProBNP Lev-
els between Groups. The level of serum hs-CRP (median
1.023mg/L, range 0.03 ∼ 5.379mg/L) was signiﬁcantly lower
in all 106 patients than that in controls (median 3.147mg/L,
range 0.08 ∼ 7.36mg/L, P = 0.012). The level of serum NT-
proBNP (median 64.56pg/mL, range 21.35 ∼ 145.51pg/mL)
in all 106 patients was higher than that in controls (median
16.74pg/mL, range 12.43 ∼ 61.25pg/mL, P<0.001). The
subjects were subdivided into low- and average-to-high risk
groups according to hs-CRP cutoﬀ level. Proportion of who
had higher hs-CRP levels (≥3mg/L) was lower in patient
group (29, 27.36%; 51, 48.11%; P = 0.003). With a cutoﬀ
point of 125pg/mL (the single cutoﬀ point for outpatients
under 75 years of age), 17 HCV-infected patients (16.04%)
and 4 controls (3.77%) had high NT-proBNP levels (P =
0.006). E, E/A, E
 ,a n dA
  were signiﬁcantly lower among
patients withhigh NT-proBNP levels(>125pg/mL),whereas
A, E/E
 , and DT were higher (Table 3).
3.3. Correlation of Serum hs-CRP Levels and NT-ProBNP
Levels. When all patients and controls were included, hs-
CRP did not correlate signiﬁcantly with NT-proBNP (r =
0.169, P = 0.121). However, in HCV-infected patients
group, simple regression analysis demonstrated a statistically
signiﬁcant linear correlation between hs-CRP and NT-
proBNP (r = 0.392, P = 0.017). Furthermore, among those
who had higher hs-CRP levels (≥3mg/L), NT-proBNP was
signiﬁcantly increased (65.41∼157.63pg/mL versus 22.56 ∼
42.41pg/mL,P<0.001).Inaddition,thesepatientshadelder
age (59.37 ± 10.12 versus 51.97 ± 11.81, P = 0.002) and
higher BMI (27.21 ±3.22 versus 22.31 ±3.45, P<0.001).
3.4. Correlation of Serum hs-CRP Levels and Echocardio-
graphic Variables in HCV-Infected Patients. Our previous
study which enrolled 90 HCV-infected patients has demon-
strated that mild diastolic dysfunction maybe exist in HCV-
infectedpatients[4].Atthepresentstudy,E,E
 ,andE/Awere
lower in HCV-infected patients than that in control group,
respectively, and E/E
  was higher (Table 4). Correlation of
serum hs-CRP levels and echocardiographic variables were
analyzed in patients group. Univariate echocardiographic
correlates of serum hs-CRP levels are presented in Table 5.
Simple regression analysis demonstrated a statistically sig-
niﬁcant linear correlation between hs-CRP levels and mitral
E/E
  (r = 0.114, P = 0.024).
3.5. Independent Correlates of Serum hs-CRP Levels. The
serum hs-CRP levels between sexes showed no signiﬁcant
diﬀerences. There was no signiﬁcant correlation between
levelofhs-CRPandserumHCVRNAtiter(r =− 0.197, P =
0.242). Age and BMI were positively correlated with Log
hs-CRP, respectively (r = 0.332, P<0.001; r = 0.124,4 Mediators of Inﬂammation
Table 4: Echocardiographic measurements between groups.
Variables Patients
(N = 106)
Controls
(N = 106) P value
LVDd (mm) 48.23 ±4.31 47.87 ±3.54 0.507
LVPWd (mm) 9.46 ±1.73 9.13 ±1.82 0.177
IVSd (mm) 9.75 ±1.66 9.82 ±1.45 0.744
E( c m / s )∗ 69.84 ±13.43 87.54 ±16.27 <0.01
A( c m / s ) 6 2 .13 ±10.37 59.84 ±11.32 0.126
E/A∗ 1.13 ±0.34 1.47 ±0.41 <0.01
DT (ms) 175.4 ±26.7 177.4 ±24.9 0.573
E  (cm/s)∗ 7.28 ±2.42 9.83 ±2.74 <0.01
A  (cm/s) 10.51 ±2.84 9.98 ±2.94 0.183
E/E ∗ 9.77 ±2.45 8.86 ±2.74 0.012
LVEF (%) 64.73 ±7.45 66.46 ±7.73 0.099
FS (%) 38.54 ±4.62 39.15 ±4.82 0.348
Abbreviations: LVDd, left ventricular diastolic diameter; LVPWd, left ven-
tricular posterior wall diastolic thickening; IVSd, interventricular septum
diastolic thickening; E, peak early diastolic transmitral ﬂow; A, peak late
diastolic transmitral ﬂow; E , peak early diastolic annular velocity; A ,p e a k
late diastolic annular velocity; E/E , the ratio of E to E ;D T ,d e c e l e r a t i o n
time; LVEF, left ventricular ejection fraction; FS, fractional shortening
Data are expressed as mean ± SD.
∗A P value of less than 0.05 was considered statistically signiﬁcant.
Table 5: Correlation coeﬃcients of linear regression analysis
between hs-CRP and echocardiographic parameters in patients
group.
Log hs-CRP
Variable r Value P Value
LVDd (mm) 0.134 0.114
LVPWd (mm) 0.024 0.387
IVSd (mm) 0.162 0.643
LVEF (%) −0.250 0.521
FS (%) −0.630 0.324
E (cm/s) 0.377 0.721
A (cm/s) 0.245 0.153
E/A 0.312 0.330
DT (ms) −0.162 0.176
E  (cm/s) 0.234 0.087
A  (cm/s) 0.456 0.063
E/E ∗ 0.114 0.024
Abbreviations: LVDd, left ventricular diastolic diameter; LVPWd, left ven-
tricular posterior wall diastolic thickening; IVSd, interventricular septum
diastolic thickening; LVEF, left ventricular ejection fraction; FS, fractional
shortening; E, peak early diastolic transmitral ﬂow; A, peak late diastolic
transmitral ﬂow; DT, deceleration time; E , peak early diastolic annular
velocity; A , peak late diastolic annular velocity; E/E , the ratio of E to E 
∗A P value of less than 0.05 was considered statistically signiﬁcant.
P = 0.021). Entering baseline characteristics and echocar-
diographic that were signiﬁcant on univariate analysis into
the multivariate analysis revealed that the signiﬁcant inde-
pendent correlates were older age (β  = 0.031, P = 0.025),
NT-proBNP (β  = 0.024, P = 0.017), and R2 = 0.13 (P =
0.016) for the multivariate model (Table 6).
Table 6: Multivariable linear regression for Log hs-CRP as depen-
dent variable.
Variable ββ   P value
age (y)∗ 0.044 0.031 0.025
NT-proBNP∗ 0.012 0.024 0.017
BMI 0.027 0.164 0.098
E/E  0.124 0.235 0.138
Abbreviations: E/E , the ratio of E to E ; β: Regression coeﬃcient; β :
standardized coeﬃcient
∗A P value of less than 0.05 was considered statistically signiﬁcant.
4. Discussion
Ourstudyistheﬁrsttoinvestigateassociationbetweenserum
hs-CRP and NT-proBNP levels in HCV-infected patients.
The most important result is that hs-CRP levels were
associated with NT-proBNP levels in HCV-infected patients,
although serum hs-CRP level decreased signiﬁcantly in
HCV-infected patients.
CRP is a component of the “acute phase response”
associated with infection, inﬂammation, and tissue dam-
age. Over the last decades, evidence has accumulated that
systemic inﬂammatory activity plays a key pathogenic role
in atherosclerosis and CVD. Elevated serum CRP level,
as detected by the hs-CRP assay, has been shown to be
a stronger predictor of incident cardiovascular events in
healthy men than LDL cholesterol and to be additive to the
Framingham risk score [8] and was consistently found to
be an independent predictor of CVD [7]. Interestingly, in
our study, hs-CRP concentrations were markedly lower in
patients group, which appears paradoxical in the presence of
chronic inﬂammation. While this ﬁnding has been reported
in previous study in 1996 [9], similarly, previous study
showed HCV-infected patients initiating interferon alfa-2b
treatment had lower baseline CRP than uninfected controls
[10].Floris-Mooreetal.reportedthatanassociationoflower
serum lipid and CRP levels with HCV infection in HIV-
infected men [11]. In addition, Skowro´ nski et al. reported
that CRP levels in diabetic HCV patients were lower than
that in diabetic patients without HCV infection [12]. On
the contrary, Huang et al. showed that the mean hs-CRP
level of chronic HCV infection patients was signiﬁcantly
higher than that of healthy controls [13]. Since interferon α
therapy may be associated with the levels of hs-CRP [10, 13],
patients treated with interferon α from less than six months
should be excluded in Huang’s study. The exact mechanism
for that hepatitis C linked with lower hs-CRP level is not
known. The present data showed that hs-CRP did not
correlate with serum HCV RNA titer. Thus, it suggests that
other factors, rather than viral replication, may contribute to
HCV-associated reduction in hs-CRP levels. Impaired liver
function associated with chronic hepatitis C may lead to
depressed production of hs-CRP.
These paradoxical ﬁndings highlight the need to assess
the predictive value of hs-CRP as a surrogate cardiovascular
risk marker in HCV-infected population. In present study,
although correlation between hs-CRP and NT-proBNP was
not found when all patients and controls were included,Mediators of Inﬂammation 5
there was a statistically signiﬁcant linear correlation between
NT-proBNP and hs-CRP in HCV-infected patients group.
NT-proBNP has been demonstrated to be independent risk
markers in heart failure patients [14], and in patients with
acute coronary syndrome [15, 16], and also in nonhospi-
talized subjects without known cardiovascular disease [17].
One study has showed that, in patients with heart failure
from HCV myocarditis, NT-proBNP is a more sensitive
marker of myocardial injury than cardiac troponins [18].
Antonelli et al. demonstrated that patients with hepatitis
C showed signiﬁcantly higher plasma NT-proBNP levels
than healthy controls [19]. Our previous data showed that
increased NT-proBNP might be a marker for detecting
subclinicalLVdiastolicdysfunctioninHCV-infectedpatients
[4]. The ﬁnding of the present study obtained in HCV-
infected patients with diﬀerent serum NT-proBNP levels
was in line with the previous result, which showed an
evidence for diastolic dysfunction in HCV-infected patients
with high NT-proBNP levels (>125pg/mL). The present
data demonstrated that hs-CRP levels possibly associated
with cardiovascular events risk in HCV-infected population,
althoughhs-CRPlevelsofpatientgroupdecreasedcompared
with healthy controls. Furthermore, we investigated whether
hs-CRP-associated LV diastolic dysfunction. The univariate
linear regression analysis demonstrated a signiﬁcant corre-
lation between hs-CRP and E/E
  in HCV-infected patients.
However, this factor was the signiﬁcant confounding factors,
because that signiﬁcant independent correlates of serum hs-
CRP were older age and NT-proBNP for the multivariate
model.
Some limitations of our study deserve to be discussed.
Firstly, the number of patients was relatively small and prob-
ably the characteristics diﬀer from the general population.
Secondly, follow-up data that may show elevated hs-CRP
levels are associated with adverse cardiac events are lacking.
5. Conclusion
In summary, the ﬁndings of the present study may have
important implications for patients with HCV infection.
Although the level of serum hs-CRP decreased signiﬁcantly,
there was a signiﬁcant association between hs-CRP and NT-
proBNP in HCV-infected patients. The predictive value and
application of hs-CRP as a surrogate cardiovascular risk
marker should have been evaluated in CVD patients in
conjunction with HCV infection, and screening for HCV
should be considered prior to assessment of cardiovascular
risk, because the results may aﬀect the cardiovascular risk
scoring.
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